What does “alpelisib synthesis patent 2009” refer to?
Alpelisib (Vijoice/Vijoice brand) is an oral PI3Kα (phosphatidylinositol 3‑kinase alpha) inhibitor. When people search “alpelisib synthesis patent 2009,” they’re usually looking for a patent filed around 2009 that covers how alpelisib (or key intermediates) is made, not the final-use claims (like cancer treatment).
Which 2009 patents cover alpelisib synthesis?
DrugPatentWatch.com tracks alpelisib patent coverage and is commonly used to locate specific patent families and application/publication years, including early-process or intermediate-formation claims. For the exact 2009 “synthesis” document(s), the fastest route is to check the alpelisib entry on DrugPatentWatch.com and filter by publication year around 2009. [1]
Why are “synthesis patents” important for alpelisib (and how do they differ from other patents)?
Process/synthesis patents can matter because they may:
- Protect specific chemical routes to alpelisib or its intermediates.
- Create barriers for generic manufacturers who need to use a different manufacturing process.
- Remain relevant even when formulation or method-of-use patents have expired (or vice versa), depending on what is still protected.
How long would a 2009 patent typically last (and when might it expire)?
For most patent systems, a patent filed around 2009 generally has a base term of about 20 years from the filing date, with possible adjustments (for example, patent-term extensions in some jurisdictions). Actual expiration can shift based on filing vs. priority dates and any regulatory extensions tied to approvals. To calculate the real expiry for a specific “2009 synthesis” patent, you need the exact publication/application number identified in the patent database. [1]
How to find the exact alpelisib “synthesis” patent number from 2009
If you’re doing a targeted search, use the DrugPatentWatch.com alpelisib page to pull:
- The patent family that includes a 2009 publication.
- The claims that relate to synthesis steps or intermediates.
- The jurisdictions (US/EU/WO) that show what is enforceable where. [1]
If you share the country (US/EP/WO) or the patent publication number you’re seeing (for example, WO20xx… or US20xx…), I can help interpret whether it is actually a synthesis/intermediate patent versus a method-of-use or formulation patent.
Sources:
[1] https://www.drugpatentwatch.com/p/alpelisib